Well Differentiated Liposarcoma
NCI Definition: A locally aggressive malignant neoplasm composed of mature adipocytes showing cell size variation and nuclear atypia. It is often associated with the presence of hyperchromatic multinucleated stromal cells, and varying numbers of lipoblasts. There are three histologic subtypes, sclerosing, inflammatory, and spindle cell liposarcoma. These tumors do not usually metastasize unless they undergo dedifferentiation. 
Well differentiated liposarcomas most frequently harbor alterations in MDM2 and CDK4 .
MDM2 Amplification and CDK4 Amplification are the most common alterations in well differentiated liposarcoma .
There is 1 clinical trial for well differentiated liposarcoma, of which 1 is open and 0 are completed or closed. Of the trial that contains well differentiated liposarcoma as an inclusion criterion, 1 is phase 2 (1 open).
Sitravatinib is the most common intervention in well differentiated liposarcoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.